Study of multiple sclerosis pathogenesis as the basis of its target therapy

T. V. Baidina , E. M. Kuklina , N. V. Selyanina , T. N. Trushnikova , N. V. Sursyakova , I. Yu. Danchenko , E. E. Arbuzova

Perm Medical Journal ›› 2018, Vol. 35 ›› Issue (1) : 27 -32.

PDF
Perm Medical Journal ›› 2018, Vol. 35 ›› Issue (1) :27 -32. DOI: 10.17816/pmj35127-32
Articles
research-article

Study of multiple sclerosis pathogenesis as the basis of its target therapy

Author information +
History +
PDF

Abstract

Aim. To study the antigen-presenting ability of B-cells, class IV semaphorin Sema4D (CD100) and CD72 receptor expression in the immune system of patients with multiple sclerosis (MS); to study the interaction between the KIF1B gene polymorphisms and the variants of response to preparation, changing the course of multiple sclerosis in MS patients.

Materials and methods. Patients with the established diagnosis of “Multiple sclerosis” by McDonald criteria 2010 with remitting type of the disease course were examined. Clinical method, psychometric testing, immune-enzyme analysis, immunologic method, PCR technique were used.

Results. Among patients with MS, the antigen-presenting function of B-lymphocytes was changed, semaphorin Sema4D/CD100 expression level on T-lymphocyte membrane was elevated, CD72 receptor expression on B-lymphocyte membrane was decreased. The studied phenomena are associated with a number of clinical characteristics that permits to consider them to participate in the pathogenesis of this disease.

Conclusions. Pathogenetic characteristics of multiple sclerosis are added by new data, which can be the targets for therapeutic strategies in the form of using anti-Sema4D- and anti-B-lymphocytic antibodies as immunomodulating therapy of MS.

Keywords

Multiple sclerosis / B-lymphocytes / semaphorin Sema4D / KIF1B gene

Cite this article

Download citation ▾
T. V. Baidina, E. M. Kuklina, N. V. Selyanina, T. N. Trushnikova, N. V. Sursyakova, I. Yu. Danchenko, E. E. Arbuzova. Study of multiple sclerosis pathogenesis as the basis of its target therapy. Perm Medical Journal, 2018, 35(1): 27-32 DOI:10.17816/pmj35127-32

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

1.Байдина Т.В., Акинцева Ю.В., Трушникова Т.Н. Тромбоцитарный серотонин при рассеянном склерозе и его связь с синдромом усталости. Нейрохимия 2013; 30 (3): 254.

[2]

2.Бойко А.Н. Выбор оптимального препарата для лечения рассеянного склероза. Медицинский совет 2015; 5: 78–79.

[3]

3.Куклина Е.М., Байдина Т.В., Данчен- ко И.Ю., Некрасова И.В. Семафорин Sema4D в иммунной системе при рассеянном склерозе. Бюллетень экспериментальной биологии и медицины 2014; 157 (2): 198–201.

[4]

4.Переседова А.В., Завалишин И.А. Современное состояние проблемы рассеянного склероза. Анналы клинической и экспериментальной неврологии 2009; 3 (1): 44–46.

[5]

5.Трушникова Т.Н., Медведева Е.Л., Байдина Т.В., Данилова М.А. Мозговой и цилиарный нейротрофические факторы у больных рассеянным склерозом. Журнал неврологии и психиатрии им. C.C. Корсакова 2014; 114 (10–2): 33–36.

[6]

6.Ханох Е.В., Рождественский А.С., Кудрявцева Е.А., Какуля А.В., Делов Р.А., Филипенко М.Л. Исследование наследственных факторов предрасположенности к рассеянному склерозу и особенностей его течения в русской этнической группе. Бюллетень СО РАМН 2011; 31 (1): 113–118.

[7]

7.Kumanogoh A.1., Marukawa S., Suzuki K., Takegahara N., Watanabe C., Ch'ng E., Ishida I., Fujimura H., Sakoda S., Yoshida K., Kikutani H. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 2002; S: 629–633.

RIGHTS & PERMISSIONS

Baidina T.V., Kuklina E.M., Selyanina N.V., Trushnikova T.N., Sursyakova N.V., Danchenko I.Y., Arbuzova E.E.

AI Summary AI Mindmap
PDF

208

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/